Semaglutide Pancreatitis Risk: What Trials and Labels Show

Semaglutide pancreatitis risk is serious enough to carry a label warning but hard to measure. Acute pancreatitis, a sudden inflammation of the pancreas, has been reported with semaglutide, including severe and fatal cases. Pooled placebo-controlled trials have not shown a clear increase. Both can be true. The events are rare, and trials used strict entry criteria, with some excluding people with chronic or recent pancreatitis.

Key takeaways

• Pancreatitis has been reported with semaglutide and the labels warn about it, yet a 2024 meta-analysis of 21 placebo-controlled trials found no clear increase (Endocrinología, Diabetes y Nutrición, 2024).
• The two fit together because pancreatitis is rare enough that small differences can't be ruled out, and trial programs used strict entry criteria, with some, such as STEP 6, excluding people with chronic or recent pancreatitis.
• Gallbladder problems are a label-confirmed risk with semaglutide, and gallstones are a recognized cause of pancreatitis.
• Get urgent care for persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting, and contact a healthcare provider promptly for fever, yellowing skin or eyes, or clay-colored stools.
• People with a personal or family history of medullary thyroid carcinoma (MTC, a rare thyroid cancer) or multiple endocrine neoplasia type 2 (MEN 2, an inherited condition that causes tumors in hormone-producing glands), or a history of pancreatitis, should not use these medications, and a licensed clinician screens for this.

Does semaglutide cause pancreatitis? The short answer

Pooled randomized trials have not shown that semaglutide raises pancreatitis risk, but cases are reported and the label warns about them. No clear increase is not the same as no risk.

The Wegovy label says acute pancreatitis, including fatal and non-fatal hemorrhagic (bleeding) or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists, the drug class that includes semaglutide (FDA Wegovy label, 2026). Necrotizing means part of the pancreas tissue dies, one of the most serious forms.

In the Wegovy weight-reduction trials, adjudication (a formal case review) confirmed acute pancreatitis in 4 semaglutide-treated patients (0.2 cases per 100 patient-years) and 1 placebo patient (under 0.1 per 100 patient-years) (FDA Wegovy label, 2026). With counts this small, one case more or fewer changes the picture.

Pancreatitis also has causes unrelated to the drug. These include gallstones, very high triglycerides (blood fats), obesity, insulin resistance and alcohol (CCJM, 2025). Many people starting a GLP-1 already have several, which makes individual cases hard to interpret.

Semaglutide pancreatitis risk in the meta-analyses

Pooled analyses of placebo-controlled trials found no clear increase in acute pancreatitis with semaglutide. Their confidence intervals still leave room for a small increase.

An odds ratio (OR) below 1 means fewer events on the drug than on placebo, and above 1 means more. A 95% confidence interval (CI) is the range of results the data are reasonably consistent with.

The 2024 analysis found no between-trial inconsistency (I² of 0%) and similar results across oral semaglutide and lower- and higher-dose injections (Endocrinología, Diabetes y Nutrición, 2024). The living review found no differences by drug, disease focus or dose (openRxiv preprint, 2026). The network meta-analysis figure comes from a review (CCJM, 2025).

An interval of 0.31 to 3.00 runs from a large reduction to a tripling, so the data cannot tell those apart. The evidence is consistent with no increase. It does not prove zero risk.

Why the label still warns: what trials can't see

Labels warn because trials can miss rare harms, and real-world reports include severe cases. Four gaps explain the caution.

1. Rarity. Acute pancreatitis is uncommon, so individual trials are usually underpowered to detect a difference (Endocrinología, Diabetes y Nutrición, 2024). Even the 2026 living review rests on about a hundred events.
2. Postmarketing reports. After approval, acute and necrotizing pancreatitis, sometimes resulting in death, were reported. The label notes that voluntary reports can't reliably establish frequency or causation (FDA Wegovy label, 2026).
3. Observational signals. A 2023 observational study of non-diabetic adults prescribed GLP-1s for weight loss found a higher relative risk of pancreatitis with semaglutide than with naltrexone-bupropion, though absolute numbers were low. The commentary describing it notes that such studies may be skewed by differences in baseline risk (Annals of Medicine and Surgery, 2025).
4. Biological plausibility. Researchers have proposed direct effects on the pancreas and an indirect route through gallstones (openRxiv preprint, 2026).

Can you take semaglutide after pancreatitis? The trial blind spot

The trials mostly can't answer this, because many excluded people with chronic or recent pancreatitis. Missing evidence, more than proven harm, leaves this group in a gray zone.

The STEP 6 trial record states that, as a precaution, people with chronic pancreatitis or recent acute pancreatitis were not enrolled (ClinicalTrials.gov, STEP 6). A case-report review notes that the SUSTAIN and STEP programs used stringent inclusion and exclusion criteria (Cureus, 2026). The reassuring meta-analyses therefore mostly describe people without chronic or recent pancreatitis.

The labels differ on this point.

• The 2023 Ozempic label (semaglutide's type 2 diabetes brand) says it has not been studied in patients with a history of pancreatitis and advises considering other diabetes therapies for them (FDA Ozempic label, 2023).
• The current Wegovy label lists contraindications only for a personal or family history of MTC or MEN 2 and prior serious hypersensitivity, so pancreatitis history is not one. Its Medication Guide asks patients to report past pancreas problems (FDA Wegovy label, 2026).

Some experts think the caution goes too far. The CCJM review authors cite a cohort of 2,245 patients with obesity starting GLP-1 therapy in which 49 (2.2%) developed acute pancreatitis, and prior pancreatitis was not associated with higher risk (CCJM, 2025). That is one observational cohort in an active debate, not a settled answer.

How gallbladder problems connect to pancreatitis

Semaglutide raises the risk of gallstones and gallbladder inflammation, and a gallstone that blocks the bile duct can trigger pancreatitis. Gallbladder disease is the one major pancreatitis risk factor that GLP-1s may plausibly contribute to (CCJM, 2025).

In the Wegovy weight-reduction trials, cholelithiasis (gallstones) occurred in 1.6% of people on the injection versus 0.7% on placebo. Cholecystitis (gallbladder inflammation) occurred in 0.6% versus 0.2%. Rapid weight loss can raise gallstone risk, but acute gallbladder disease was more frequent with Wegovy even after accounting for weight lost, and it can occur without rapid loss (FDA Wegovy label, 2026).

A 2022 meta-analysis in JAMA Internal Medicine pooled 76 randomized trials of GLP-1 receptor agonists (JAMA Internal Medicine, 2022). It found a relative risk (RR), the risk on the drug divided by the risk without it, of 1.37 (95% CI 1.23–1.52) for gallbladder or biliary disease. Risk was higher at higher doses, with longer use and when the drugs were used for weight loss. Medscape's coverage quotes the authors describing the absolute increase as small, about 27 extra cases per 10,000 people treated per year.

The proposed mechanism is straightforward. Rapid weight loss sends more cholesterol into bile, smaller or less frequent meals mean the gallbladder empties less often, and GLP-1 receptor agonists slow biliary motility (the movement of bile). Together these favor sludge and stones that can block the duct (CCJM, 2025).

Pancreatitis symptoms on semaglutide: when to get help now

Persistent or severe abdominal pain, sometimes spreading to the back, needs prompt medical care. Ordinary early nausea is a different thing.

The first two rows reflect the label and Medication Guide (FDA Wegovy label, 2026). For milder effects that typically come and go, see GLP-1 side effects week by week. Telehealth is not for emergencies. Severe abdominal pain, high fever or yellowing of the skin or eyes warrant in-person emergency care.

How access works through New Blue

New Blue's Semaglutide GLP-1 pathway uses a structured online intake that a licensed clinician reviews. Screening for pancreatitis, gallbladder disease, MTC and MEN 2 happens at that step.

1. You complete an asynchronous intake covering any history of pancreatitis or gallbladder disease, any personal or family history of MTC or MEN 2, and other relevant conditions. Answer fully, because the screening depends on it.
2. A licensed clinician reviews it. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
3. If appropriate and prescribed, a licensed partner pharmacy ships the medication directly to you.

People with a personal or family history of MTC or MEN 2, or a history of pancreatitis, should not use these medications, and a licensed clinician screens for this. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.

Compounded semaglutide has the same active ingredient as Ozempic and Wegovy (FDA-approved brand products). Compounded medications are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

Availability varies by state. The Semaglutide GLP-1 pathway ships to every state New Blue Health serves except North Dakota, and the Tirzepatide GLP-1 pathway has the same North Dakota limit. Check state availability. If treatment isn't appropriate, refunds follow our refund policy. For current pricing, see the Semaglutide GLP-1 pathway page.

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

Frequently Asked Questions

I had pancreatitis once, years ago. Can I use semaglutide?

The evidence doesn't settle it. Trials such as STEP 6 excluded people with chronic or recent pancreatitis, and the 2023 Ozempic label says the drug was not studied in people with a pancreatitis history. A history of pancreatitis is a reason not to use these medications, and a licensed clinician makes the eligibility decision.

My lipase came back high. Does that mean I have pancreatitis?

Not by itself: lipase and amylase are digestive enzymes made by the pancreas, and the Wegovy label reports average rises in both during trials. The label says their significance is unknown without other signs or symptoms of pancreatitis. Discuss the result with your clinician, and seek care right away if you also have severe or persistent abdominal pain.

Is tirzepatide any different on pancreatitis risk?

A 2026 living review, a preprint that has not been peer reviewed, pooled placebo-controlled trials of semaglutide and tirzepatide and found no significant difference in pancreatitis events by drug. That doesn't make either one risk-free, and the same screening principles apply. For the broader comparison, see how the semaglutide and tirzepatide pathways differ.

Do the trial results apply to compounded semaglutide?

Not directly. The trials and labels studied FDA-approved brand products. Compounded semaglutide has the same active ingredient but is not FDA-approved and was not the product tested. For context, read branded vs compounded GLP-1 options.

Does the Wegovy label list pancreatitis history as a contraindication?

No. The current Wegovy label lists contraindications for a personal or family history of MTC or MEN 2 and prior serious hypersensitivity, while warning about pancreatitis and asking patients to report past pancreas problems. A licensed clinician reviews any history of pancreatitis during intake, and people with that history should not use these medications.

Sources

1. WEGOVY (semaglutide) injection / tablets: Highlights of Prescribing Information and Medication Guide (revised 05/2026). U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf
2. OZEMPIC (semaglutide) injection: Prescribing Information (2023 label version). U.S. Food and Drug Administration, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
3. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinología, Diabetes y Nutrición (English ed.), 2024. https://doi.org/10.1016/j.endien.2024.03.012
4. GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis. openRxiv (preprint, not peer reviewed), 2026. https://doi.org/10.64898/2026.03.19.26348844
5. Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce. Cleveland Clinic Journal of Medicine, 2025. https://doi.org/10.3949/ccjm.92a.24113
6. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35344001/
7. STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity. ClinicalTrials.gov registry record NCT03811574 (year not listed). https://clinicaltrials.gov/study/NCT03811574
8. Off-label ozempic and pancreatitis: legitimate concern or overblown fear? Annals of Medicine and Surgery, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12577794/
9. Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report. Cureus, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12919507/

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate for you, are made by a licensed clinician based on your history and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.